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Here, we show CRISPR/Cas9-based targeted somatic multiplex-
mutagenesis and its application for high-throughput analysis of
gene function in mice. Using hepatic single guide RNA (sgRNA)
delivery, we targeted large gene sets to induce hepatocellular
carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). We
observed Darwinian selection of target genes, which suppress tumor-
igenesis in the respective cellular/tissue context, such as Pten or
Cdkn2a, and conversely found low frequency of Brca1/2 alterations,
explaining mutational spectra in human ICC/HCC. Our studies show
that multiplexed CRISPR/Cas9 can be used for recessive genetic screen-
ing or high-throughput cancer gene validation in mice. The analysis of
CRISPR/Cas9-induced tumors provided support for amajor role of chro-
matin modifiers in hepatobiliary tumorigenesis, including that of ARID
family proteins, which have recently been reported to be mutated in
ICC/HCC. We have also comprehensively characterized the frequency
and size of chromosomal alterations induced by combinatorial sgRNA
delivery and describe related limitations of CRISPR/Cas9 multiplexing,
as well as opportunities for chromosome engineering in the context of
hepatobiliary tumorigenesis. Our study describes novel approaches to
model and study cancer in a high-throughput multiplexed format that
will facilitate the functional annotation of cancer genomes.
in vivo CRISPR/Cas9 | somatic multiplex-mutagenesis | hepatocellular
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For decades, a major bottleneck in cancer research has beenour limited ability to identify genetic alterations in cancer.
The revolution in array-based and sequencing technologies and
the recent development of insertional mutagenesis tools in animal
models enable the discovery of cancer-associated genetic alter-
ations on a genome-wide scale in a high-throughput manner. Next-
generation sequencing (NGS) of cancer genomes and transposon-
based genetic screening in mice, for example, are currently creating
large catalogs of putative cancer genes for principally all cancer
types (1–3). A challenge for the next decades will be to validate
the causative cancer relevance of these large gene sets (to distin-
guish drivers from passengers) and to understand their biological
function. Moreover, pinpointing downstream targets of mutated
cancer genes or drivers among the thousands of transcriptionally
or epigenetically dysregulated genes within individual cancers is
complex and limited by the lack of tools for high-throughput
functional cancer genomic analyses.
The development of technologies for targeted manipulation of the
mouse germ line has opened tremendous opportunities to study gene
function (4, 5). Mouse models recapitulate the extensive biological
complexity of human cancer and have given insights into many
fundamental aspects of the disease that can be studied only at
an organismal level (6). However, the speed and efficiency of
such studies is limited by the long time frames needed to ge-
netically engineer, intercross, and breed mouse cancer models.
The prokaryotic clustered regularly interspaced short pal-
indromic repeats (CRISPR)/CRISPR associated protein 9
(Cas9) system has been recently adapted for genetic engi-
neering in mammalian cells (7–13). Using 20-bp single guide
RNA sequences (sgRNAs), the endonuclease Cas9 can be di-
rected to desired genomic positions to cause a double strand
break. This break is repaired by nonhomologous end joining,
which commonly leaves a short insertion or deletion (indel),
allowing homozygous disruption of the targeted gene. Recent
studies showed that CRISPR/Cas9 is functional in germ cells and
somatic cells of mice and can be used for gene editing and cancer
induction in the lung and the biliary compartment (14–20).
Targeting of Pten and p53 in the liver was reported to induce
Significance
Assigning biological relevance and molecular function to large
catalogues of mutated genes in cancer is a major challenge.
Likewise, pinpointing drivers among thousands of transcrip-
tionally or epigenetically dysregulated genes within a cancer is
complex and limited by the lack of tools for high-throughput
functional cancer genomic analyses. We show here for the first
time, to our knowledge, application of the CRISPR/Cas9 genome
engineering system for simultaneous (multiplexed) mutagenesis of
large gene sets in adult mice, allowing high-throughput discovery
and validation of cancer genes. We characterized applications of
CRISPR/Cas9 multiplexing, resulting tumor phenotypes, and limi-
tations of the methodology. By using defined genetic or environ-
mental predisposing conditions, we also developed, to our
knowledge, the first mouse models of CRISPR/Cas9-induced he-
patocellular carcinoma and show how multiplexed CRISPR/Cas9
can facilitate functional genomic analyses of hepatobiliary cancers.
Author contributions: J.W., R.Ö., and R.R. designed research; J.W., R.Ö., M.F., U.E., I.H.,
S.M., R.M., N.G., U.G., B.F., A. Segler, D.Y., S.L., A. Strong, J.d.l.R., K.U., and F.Y. per-
formed research; P.L., J.C., G.S.V., R.M.S., G.S., K.U., F.Y., R.B., M.H., I.V., D.S., and A.B.
contributed new reagents/analytic tools; J.W., R.Ö., M.B., K.S., T.E., I.E., K.U., F.Y., R.B.,
M.H., I.V., D.S., and R.R. analyzed data; and J.W., R.Ö., and R.R. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
1J.W. and R.Ö. contributed equally to this work.
2To whom correspondence should be addressed. Email: roland.rad@tum.de.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1512392112/-/DCSupplemental.
13982–13987 | PNAS | November 10, 2015 | vol. 112 | no. 45 www.pnas.org/cgi/doi/10.1073/pnas.1512392112
intrahepatic cholangiocarcinoma (ICC) (16), but CRISPR/Cas9-
based modeling of hepatocellular carcinoma (HCC) (which ac-
counts for 90% of liver cancers) has not been achieved so far,
nor has complex combinatorial gene targeting. We therefore
developed CRISPR/Cas9 hepatic mutagenesis approaches in
multiplexed formats for high-throughput in vivo applications.
Results and Discussion
Inducing HCC and ICC by Hepatic Delivery of Multiplexed CRISPR/Cas9
in Adult Mice. To deliver CRISPR/Cas9 to hepatocytes, we used
hydrodynamic tail vain injection (HTVI) (21). We generated a
vector (CRISPR-SB) carrying sgRNA and Cas9 expression cassettes
(11) flanked by Sleeping Beauty (SB) inverted repeats (SI Appendix,
Fig. S1). HTVI of CRISPR-SB and an SB-transposase vector (hSB5)
enables, in principle, both transient CRISPR/Cas9 expression from
episomal plasmids and long-term expression from SB-mobilized/
genome-integrated vectors. Using HTVI of two different vectors
followed by fluorescence-based detection of their cellular delivery,
we found that multiple plasmids can enter a cell (SI Appendix, Fig.
S2 and Supplementary Methods), providing a rationale for combina-
torial CRISPR/Cas9-based tumor suppressor gene (TSG) targeting.
NGS recently discovered many putative novel ICC/HCC cancer
genes (22–29), but their functional validation is largely lacking.
Based on a literature search (SI Appendix, Table S1), we have
chosen to target (i) bona fide TSGs that are often mutated, de-
leted, or epigenetically silenced in ICC/HCC (e.g., Trp53, Smad4,
Pten, Cdkn2a, and Apc), (ii) TSG Arid1a, a novel commonly
mutated chromatin modifier in ICC (and less frequently in HCC),
and (iii) TSG Tet2, a putative (negatively regulated) downstream
target of the ICC oncogenes Idh1/Idh2. We also targeted the
TSGs Brca1/2, which are not or only rarely altered in ICC/HCC.
Targeting efficiencies of multiple sgRNAs per gene were vali-
dated in vitro using T7E1 assays before choosing best performing
sgRNAs for HTVI (SI Appendix, Fig. S3). A dominant pathway
activated in ICC/HCC is Ras/MAPK signaling (30, 31). We have
therefore used oncogenic KrasG12D to accelerate tumorigenesis.
We coinjected hSB5 transposase plasmid and 10 CRISPR-SB
vectors and confirmed their successful delivery 2 wk later: real
time quantitative PCR (qPCR) showed a random distribution
pattern of the 10 sgRNAs in most animals (Fig. 1 A and B). We
euthanized eight mice 20–30 wk post-HTVI and collected 21
macroscopic liver tumors (Fig. 1C). At this stage, mice typically
had one to three small tumors (1–3 mm), occasionally more. We
found both ICCs and HCCs (Fig. 1C and SI Appendix, Figs. S4 and
S5). Conventional type ICCs showed CK19 positivity, reflecting
biliary differentiation, and featured a Collagen-4–positive stromal
reaction like the human disease (Fig. 1C and SI Appendix, Fig.
S5). These early onset cancers were triggered by CRISPR/Cas9
because KrasG12D alone induces only low-penetrance late-onset
tumors: We observed no ICCs/HCCs in a control cohort of 53 Alb-
Cre;KrasLSL-G12D/+ mice aged up to 38 wk. Furthermore, we didn’t
observe ICCs/HCCs in Alb-Cre;KrasLSL-G12D/+ control cohorts
injected with hSB5 and Cas9-only expressing CRISPR-SB (n = 8).
Quantitative Analysis of Target Site Mutations in Healthy Livers And
Cancers. We performed NGS of PCR-amplified target sites in tu-
mors and related healthy livers (Fig. 2). Because sequence reads with
large deletions are often filtered out during mapping using standard
bioinformatics tools, we used manually inspected/mapped capillary
sequencing data of cloned PCR products (SI Appendix, Fig. S6) to
optimize the algorithms for NGS-based high-throughput indel de-
tection. Whereas Cas9-only injected control mice had no mutations
at the CRISPR/Cas9 target sites, we found a total of 167 indels in the
21 tumors (Fig. 2 A and B). The majority were small and located
at the position of the Cas9 double strand break insertion [3 bp up-
stream of the protospacer adjacent motif (PAM)]. Large deletions
(>50 bp) were rare (Fig. 2 and SI Appendix, Figs. S7 and S8).
We next compared the frequency of CRISPR/Cas9-induced
frame shifts causing indels at target sites in tumors and healthy
livers from the same mice (Fig. 2C and detailed view in SI
Appendix, Fig. S9). In-frame deletions <10 bp are less likely to
have functional consequences and are therefore shown only in










































































Fig. 1. Hepatic delivery of multiplexed CRISPR/Cas9 for somatic mutagenesis in mice. (A) Genes targeted simultaneously upon hydrodynamic tail vein in-
jection (HTVI). For details of the two-vector system, see SI Appendix, Fig. S1. (B) Analysis of healthy livers 2 wk post-HTVI. (Upper) Quantification of hSpCas9
DNA copies using qPCR; Error bars, SEM from triplicate determinations. (Lower) Quantitative analysis of sgRNA distribution using qPCR with guide-specific
forward primers and a generic reverse primer (color code from A). (C) Microscopic images of CRISPR/Cas9-induced tumors in Alb-Cre;KrasLSL-G12D/+ mice. ICC,
intrahepatic cholangiocarcinoma. (Top) H&E staining. (Middle) Cytokeratin 19 (CK19) IHC staining. HCC, hepatocellular carcinoma. (Bottom) Two H&E-stained
HCCs. (Scale bars: Left panel in Top and Middle row, 50 μm; Right panel in Top and Middle row, 400 μm; both images in Bottom row, 100 μm.)






tumor-bearing mice exhibited no or only few mutations with
low mutant read frequencies (MRFs) (fraction of mutant-reads/
all-reads at individual target sites) (Fig. 2C). In contrast, all tumors
had several mutations above the 4% MRF threshold, which was
used to exclude their origin in healthy tissue (Fig. 2C). In Tu1, for
example, MRFs reached up to 62% for individual target loci,
reflecting clonal expansion of mutations. Further details about
the type and frequency of mutations at individual positions are
shown in SI Appendix, Fig. S9 and Table S2.
Differences of MRFs between tumors can at least partly be
explained by the varying content of nonneoplastic cells. Tu2, for
example, which generally had lower MRFs at mutated target sites
than Tu1, also had a significantly smaller tumor/normal cell ratio
(Fig. 2D and SI Appendix, Fig. S5). In contrast, extensive differ-
ences between MRFs at different target sites within one tumor
could reflect intratumor heterogeneity, as shown later.
Cancer-Relevant Mutations Undergo Positive Selection. A global com-
parison of the incidence of CRISPR/Cas9-induced target site mu-
tations across tumors showed a nonrandom distribution (P = 2.2 ×
10−15; χ2 test). Pten, for example, was mutated in all 21 tumors
whereas Brca1 or Brca2 mutations were largely absent (only one
low-frequency Brca1 mutation in Tu1). This distribution suggests
that biologically relevant mutations are selected for in vivo. The
high incidence of Pten mutations can indeed be explained by the
key importance of PI3K signaling in hepatobiliary tumorigenesis in
humans and mice (32–34). Likewise, the lack of Brca1/2 mutations
reflects their extremely rare alteration in human ICC/HCC (SI
Appendix, Table S1). Overall, several genes were targeted signifi-
cantly more frequently than Brca1/2, including Pten (P = 6.4 × 10−15),
Apc (P = 9.3 × 10−7), Tet2 (P = 6.6 × 105), Cdkn2a-ex2 (P =
0.0007), p53 (P = 0.007), and Arid1a (P = 0.02; Fisher’s exact test).
The possibility of technical problems underlying the low in-
cidence of Brca1/2 mutations in tumors can be excluded because
(i) surveyor assays in vitro confirmed similar efficiencies of Brca1/2
targeting to other loci (Fig. 2E), and (ii) the “background” Brca1/2
mutation rate in healthy livers was similar to other target genes
(SI Appendix, Table S2). We therefore conclude that Darwinian
selection of indels with pathogenetic relevance in the specific tis-
sue context drives tumorigenesis in our model.
Another level of evidence for in vivo selection comes from the
comparison of the two Cdkn2a sgRNAs that we used: one tar-
geting exon-1β to inactivate p19Arf and the second directed against
exon-2 to disrupt both p19Arf and p16Ink4a. Whereas Cdkn2a-ex2
was mutated in 33% (7/21) of tumors, no mutations above the
“background” mutation rate in healthy liver were found in
Cdkn2a-ex1β (P = 0.009; Fisher’s Exact test) (Fig. 2C). This ob-
servation suggests selective pressure for the double-mutant and
also reflects the predominant CDKN2A inactivation pattern in
human hepatobiliary cancers. To confirm that sgRNAs against
both exons are in fact functional, we performed surveyor assays,
which showed similar efficiencies of Cdkn2a-ex2 and Cdkn2a-
ex1β targeting (SI Appendix, Fig. S10).
The pathogenic relevance of TSGs like Pten or Trp53 in ICC/HCC
has been shown in vivo (35, 36). For Arid1a, which was recently




Fig. 2. Analysis of CRISPR/Cas9 target site mutations in healthy liver and liver tumors. (A) Pie chart showing the type (deletion or insertion) and size of all indels
derived from liver tumors (n = 21) of Alb-Cre;KrasLSL-G12D/+ mice (n = 8) 20–30 wk after HTVI of hSpCas9 and ten sgRNAs. (B) Examples of indel sequence context in
selected tumors for Arid1a/Tet2/Pten. PAM, protospacer adjacent motif. WT, WT sequence. (C) Mutant read frequencies (MRFs) at individual target sites as de-
termined by amplicon-based next-generation sequencing. Multiple indels at individual target sites (shown in detail in SI Appendix, Fig. S9) are presented here as
combinedMRFs. Frame-shift causing indels withMRFs >1%and 4%are shown for healthy livers and tumors, respectively. Pos, tumors with Cdkn2a-ex1β/Cdkn2a-ex2
fusions. Small macroscopic tumors (<1 mm) were used entirely for genomic analyses (unclassified; no histology available). (D) Comparison of cancer cell to non-
neoplastic cell contents in Tu1 and Tu2. CK19 staining marks ICC. (Scale bars: Upper, 400 μm; Lower, 100 μm.) (E) Surveyor assays to assess CRISPR/Cas9 efficiency
upon transient transfection of the mouse pancreatic cancer cell line PPT-53631. Indel frequencies are indicated. Cell lines were transfected with the target sgRNA (+)
or a control sgRNA (−). Because PPT-53631 has homozygous Cdkn2a deletions, Cdkn2a sgRNAs were tested in a different cell line (PPT-4072) (SI Appendix, Fig. S10).
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such biological information is lacking. We found Arid1a altera-
tions in 24% of tumors (Fig. 2C). In addition, 80% (11/14) of
hepatobiliary cancers (3/3 ICCs and 8/11 HCCs) induced in a second
HTVI approach targeting a larger set of genes (described below)
had CRISPR/Cas9-induced mutations of Arid1a and/or Arid1b, an-
other chromatin modifier that was recently discovered to be fre-
quently mutated in ICC/HCC. These observations strongly support a
role of chromatin modifying enzymes in hepatobiliary tumorigenesis.
CRISPR/Cas9 has been recently adapted for genetic screening
in vitro (37–39) and also in a transplantation model (40). We show
that somatic mutagenesis and cancer gene discovery are also feasible
directly in vivo. A surprising finding was the high frequency of
CRISPR/Cas9-induced mutations in Tet2 (particularly in ICCs) (Fig.
2C). Its tumor suppressive function might be linked to IDH1/IDH2,
which carry oncogenic mutations in >10% of ICCs (23, 24, 41),
leading to dioxigenase inhibition by 2-hydroxyglutarate production
(42, 43). Among the 70 2OG-dependent dioxigenases, TET2 is con-
sidered a promising cancer-relevant target: TET2 and IDH1/2
mutations induce similar hypermethylation phenotypes (41, 44)
and are mutually exclusive in AML, suggesting similar effects on
cellular transformation (45). TET2 is not mutated in human ICC,
but IDH1/2 alterations are associated with impaired TET2 function
(41). Our data support TET2’s pathogenetic relevance in ICC and
exemplify how genetic screening can pinpoint cancer genes that are
not mutated, but dysregulated by other means.
Intratumor Heterogeneity in a Small Subset of CRISPR/Cas9-Induced
Cancers. In some cancers (e.g., Tu1, -4, -5, and -21), MRFs differed
extensively between individual target sites, and often more than two
mutations at individual sites existed within a tumor (Fig. 2 and SI
Appendix, Fig. S9). One explanation for this observation could be that
some mutations occur in the transfected founder cell whereas others
happen only after the first cell division in subsequent daughter cells.
To explore this possibility, we compared three different regions in
Tu1 (SI Appendix, Fig. S11): the large area R1 and the small
microdissected areas R2 (with a well-differentiated tubular growth
pattern) and R3 (showing poor differentiation and more solid
growth). Target sites sequencing revealed that, even within R2/R3,
many MRFs were low, suggesting additional intraregional minority
clones and a complex subclonal structure, which is only partly re-
solved. The only mutation with consistently high MRFs in all three
regions was Cdkn2a-ex2, suggesting its position at the trunk of a
phylogenetic tree. R2/R3 comparison revealed substantial differ-
ences regarding driver mutations in dominant clones (SI Appendix,
Fig. S11C), with Smad4-1del defining the dominant clone in R2 and
Pten-1del-b in R3, suggesting that genetic heterogeneity underlies
phenotypic intratumor diversity. The possibility of R1/R2/R3 being
independent tumors is highly unlikely because of (i) the presence of
specific high-frequency founder Cdkn2a mutations in all three re-
gions (including a single base deletion and an 18-kb CRISPR/Cas9-
induced deletion) (SI Appendix, Fig. S9 and Table S2), and (ii) the
small size (3 mm) of this solitary tumor in an otherwise healthy liver.
Chromosomal Rearrangements Induced by Combinatorial CRISPR/Cas9
Targeting. One potential limitation of multiplexed CRISPR/Cas9
mutagenesis is that, in principle, combinatorial sgRNA targeting
could lead to undesired large chromosomal rearrangements (18,
20). To examine this possibility, we performed PCR-based screening
for all possible deletions at chromosomes that were targeted by
multiple sgRNAs (SI Appendix, Fig. S12). Out of the 105 possible
deletions in 21 tumors, we found evidence for fusion products be-
tween the Cdkn2a-ex1β and Cdkn2a-ex2 sgRNA target sites in two
cancers (Fig. 2C). In both cases the resulting deletion of ∼18 kb led
to inactivation of both p16Ink4a and p19Arf (SI Appendix, Fig. S12).
Because small indels in exon-2 mediated by a single Cdkn2a-ex2
sgRNA also inactivates both p16Ink4a and p19Arf, there is no
selective pressure beyond exon-2 mutations for the 17.7-kb de-
letion to occur. It therefore seems that this relatively small deletion
of 17.7 kb is a fairly efficient process.
We therefore next studied such potentially undesired effects of
CRISPR/Cas9 multiplexing in a scenario of higher level multi-
plexing (18 sgRNAs targeting known or putative hepatobiliary
cancer genes). Furthermore, to examine whether ICCs/HCCs




Fig. 3. Intrachromosomal fusions induced by combinatorial CRISPR/Cas9 targeting. (A) Scheme of chromosomes with two or more CRISPR/Cas9 target sites in the 18
sgRNAmultiplexing experiments. Brackets indicate the predicted sizes of possible deletions (del-1 to del-13), ranging from 16 kb to 74Mb. (B) PCR screening for all 533
possible intrachromosomal fusions in 41 liver tumors revealed four large deletions in three tumors: an 18-kb deletion (del-2, Tu24; Cdkn2a-ex1β/Cdkn2a-ex2 fusion),
two large deletions in Tu23 (del-10, Cdkn2b/Errfi1, 62Mb; del-11, Arid1a/Errfi1, 17 Mb), and another Arid1a/Errfi1 fusion in Tu31. (C) DAPI staining of metaphase
spreads of Tu23 cell line confirms the large deletion (del-10) in chromosome 4. (D) Del-2 in Tu24 and del-11 in Tu23 are detected as copy number losses by array CGH.






cancer-predisposing contexts, we have used not only the Kras-mutant
background but also a CCl4-induced liver injury model. We have
analyzed a total of 41 tumors collected in these experiments. All
cancers induced in the CCl4 context (n = 35) were HCCs whereas in
Alb-Cre;KrasLSL-G12Dmice, we found both ICCs and HCCs. Detailed
information about tumor incidences is provided in SI Appendix,
Table S3. The general conclusions drawn from target site mutation
sequencing were in concordance with our observations made in the
10 sgRNA studies: For example, the incidence of Brca1, Brca2, or
isolated Cdkn2a-ex1β mutations was very low (20%, 10%, or 7%)
whereas Pten or epigenetic regulators (Arid1a and/or Arid1b) were
hit in 93% and 78% of cancers, respectively, further confirming that
pathogenetically relevant mutations are selected for in vivo.
With respect to CRISPR/Cas9-induced rearrangements, we
screened for all 533 possible large intrachromosomal deletion/
fusion events in the 41 tumors using PCR and in a subset of tumors
also by comparative genomic hybridization (CGH) and multicolor
fluorescence in situ hybridization (M-FISH) (Fig. 3 and SI Ap-
pendix, Figs. S13 and S14). We identified four deletions in three
cancers: an 18-kb deletion at the Cdkn2a locus (Tu24), a 62-Mb
deletion between TSGs Cdkn2b and Errfi1 (Tu23), and 17-Mb
deletions between Arid1a and Errfi1 (Tu23 and Tu31). The 62-Mb
deletion identified in Tu23 by fusion-PCR was “silent” in CGH
because of its subclonal occurrence. It was, however, detectable by
FISH (1/7 metaphases positive for the deletion) (Fig. 3C). There
were no interchromosomal translocations in the cell lines analyzed
by M-FISH (n = 2) (SI Appendix, Fig. S14). Because stable in-
tegration of CRISPR/Cas9 vectors was very rare in our cancers
(integrations identified by PCR-based detection of CRISPR-SB
vectors in only 3 out of 62 tumors), we conclude that transient ex-
pression of multiplexed CRISPR/Cas9 can be sufficient to induce
one or more intrachromosomal rearrangements within a cell in vivo.
One implication of these results is that the extent of multi-
plexing will have limitations. Either it will require careful selection/
combination of target sites or the possibility of undesired chro-
mosomal damage occurring will need to be tested for. These
findings are also relevant for genome-wide in vitro CRISPR/Cas9
screening, particularly in experimental settings where multiple
sgRNAs are delivered to a cell. On the other hand, the ob-
servation that chromosome engineering is feasible somatically in
the context of liver cancer offers great opportunities. GWAS and
whole genome sequencing studies are currently identifying hun-
dreds of ICC/HCC variant hot spot regions, many of which are
located in genomic deserts, coinciding with putative regulatory
regions, such as enhancers (www.genome.gov/encode). Our re-
sults suggest that these regions can be systematically targeted using
multiplexed CRISPR/Cas9 to study their biological role in cancer.
No Off-Target Effects in CRISPR/Cas9-Induced Liver Tumors. We have
screened eight tumors for undesired off-target effects by amplicon-
based NGS of each sgRNA’s top five off-targets (at least three
exonic off-targets). We found no indels at off-target sites with a
mutant read frequency of 0.2% or higher (a cutoff used to exclude
sequencing errors for both on- and off-target site analyses). We
also screened CGH data from six tumors for 266,778 potential
intrachromosomal deletions resulting from combinations of po-
tential off-target cleavage events (1,010 and 1,550 off-target sites
for 10 sgRNAs and 18 sgRNAs, respectively) (SI Appendix, Fig.
S13). Off-target sites were defined to be potentially causative if
they were within a distance of 500,000 bp (and 20 probes or fewer)
to an aberration detected by CGH. These analyses did not identify
chromosomal deletions attributable to off-target effects.
CRISPR/Cas9-Induced Mutations Are Predominantly Biallelic. To as-
sess the incidence of biallelic vs. monoallelic target gene mutations,
we next analyzed cancer cell lines isolated from an aggressive ICC
induced by 18-sgRNA multiplexing (Fig. 4 and SI Appendix, Fig.
S15 show that these cell lines are transplantable). In contrast to all
other tumors analyzed in this study (which were identified early by
regular MRI screening and were therefore small), one animal had an
early onset large (>2 cm) tumor mass and numerous metastases to
lymph nodes, peritoneum, and lungs (SI Appendix, Fig. S16). Ex-
tensive geographical sampling of the tumor mass (n = 10) and sub-
sequent target site sequencing revealed three independent primary
cancers (Tu22, Tu23, and Tu24), with Tu24 being predominant (8/10
samples). The analysis of CRISPR/Cas9-induced indel patterns also
allowed phylogenetic tracking of metastatic clones: All metastases
(n = 9) originated from Tu24 (Fig. 4B and SI Appendix, Table S4).
Comparative indel analysis of primary tumor tissue and corre-
sponding cell lines showed that accurate estimation of MRFs is
difficult in primary cancer tissue due to stromal components (Fig.
4B and SI Appendix, Table S4). A combined quantitative analysis of
(i) indel frequencies, (ii) the presence or absence of large deletions
(fusions), and (iii) the frequency of WT reads at target sites in
these cell lines revealed that 79% of mutated target loci have
biallelic inactivation (Fig. 4C and SI Appendix, Table S5), despite
the fact that none of these tumors had stably integrated CRISPR/
Cas9. The predominant homozygous inactivation underlines the
potential of CRISPR/Cas9 for recessive genetic screening and gene
function analysis.
Hepatic loss-of-function screening has been performed using
RNAi-based gene knock-down in transplantation models (e.g.,
intrasplenic implantation of bipotent liver progenitor cells) (46)
A
B C
Fig. 4. Allelic frequencies of target site mutations and phylogenetic track-
ing of CRISPR/Cas9-induced metastatic ICC. (A) A 2-cm tumor mass (ICC) and
numerous metastases (Mets) in lungs, lymph nodes (LN), and peritoneum in a
mouse 20 wk after HTVI of 18 sgRNAs. (B) CRISPR/Cas9 target sites underwent
NGS in a total of 35 tumor/metastasis tissues and cell lines. Indel patterns
revealed three independent primary tumors. All metastases originate from
Tu24. Frame-shift causing indels with a cumulative mutant read frequency
(MRF) >4% per target site are shown for representative samples. Note that MRFs
are underestimated in cancer tissue (because of healthy stromal components)
but are accurately reflected in cell lines. Tumors with indicated fusion products
are marked as positive (pos). Asterisks indicate a lack of WT sequence. (C) Allelic
frequency of mutations in cell lines of Tu23 and Tu24 as determined by a
combined quantitative analysis of indel frequencies, presence/absence of large
fusions, and the presence/absence of WT reads.
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or by HTVI-based/transposon-mediated genome integration of
shRNAs (47). Our results show that RNAi and CRISPR/Cas9 are
complementary tools with unique beneficial characteristics, depend-
ing on the experimental context. CRISPR/Cas9-induced homozygous
gene knockout is a major advance for recessive genetic screening
whereas RNAi-based knockdown (which is typically only partial) has
advantages for the study of dosage effects or reversible phenotypes.
Likewise, the ability to perform chromosome engineering by
CRISPR/Cas9 is an important novel technological innovation but
can be disadvantageous if such effects are not desired.
Concluding Remarks
Our work describes novel approaches to model and study cancer
in mice. We provide, to our knowledge, the first demonstration
and characterization of highly multiplexed direct in vivo CRISPR/
Cas9 mutagenesis, including (i) the description of proof-of-prin-
ciple applications (genetic screening for cancer gene validation/dis-
covery), (ii) a characterization of tumor phenotypes at the genetic
level (tumor heterogeneity, allelic mutation frequency, phylogenetic
metastasis tracking, single cell cloning), and (iii) a thorough analysis/
discovery of possible caveats (frequency/size/extent of chromosomal
rearrangements). This multilayered characterization gives com-
prehensive insights into the potential and limitations of in vivo
CRISPR/Cas9 multiplexing and thus guidance for its appropriate
use. In defined genetic (KrasG12D) and liver damage models (CCl4),
we also show for the first time, to our knowledge, that CRISPR/
Cas9 somatic gene targeting can be used to induce HCC, one of
the leading causes of cancer-related death worldwide, and we
provide support for the emerging role of chromatin modifiers in
hepatobiliary tumorigenesis. Multiplexing CRISPR/Cas9 will en-
hance the speed and efficiency of assigning biological function to
DNA sequence, one of the big scientific challenges in the post-
genomic era.
Methods
A detailed description of experimental procedures is available in SI Appendix.
Briefly, CRISPR/Cas9 cleavage efficiencies were tested in vitro using T7E1 or
Surveyor assays. Hepatic delivery of CRISPR/Cas9 vectors was performed by
HTVI, as described earlier (21). All animal studies were conducted in com-
pliance with European guidelines for the care and use of laboratory animals
and were approved by the Institutional Animal Care and Use Committees
(IACUC) of Technische Universität München, Regierung von Oberbayern, and
the UK Home Office. CRISPR/Cas9 target site mutations were identified using
amplicon-based NGS. Liver tumors were characterized by immunohisto-
chemistry (IHC), CGH, and M-FISH.
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